Arca
Skip to content

IGF1R: Insulin-like growth factor 1 receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Receptor tyrosine kinase which mediates actions of insulin- like growth factor 1 (IGF1).

  • Drugs that act on it: 20
  • With a US drug page: 3
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
MasoprocolApprovedInsulin-like growth factor I receptor inhibitorInhibitor—
TeprotumumabApprovedInsulin-like growth factor I receptor antagonistAntagonist—
VeligrotugApprovedInsulin-like growth factor I receptor antagonistAntagonist—
AEW-541—Insulin-like growth factor I receptor inhibitorInhibitor—
AXL-1717—Insulin-like growth factor I receptor inhibitorInhibitor—
BIIB-022—Insulin-like growth factor I receptor inhibitorInhibitor—
BMS-754807—Insulin-like growth factor I receptor inhibitorInhibitor—
Cixutumumab—Insulin-like growth factor I receptor antagonistAntagonist—
Conteltinib—Insulin-like growth factor I receptor inhibitorInhibitor—
Dalotuzumab—Insulin-like growth factor I receptor antagonistAntagonist—
Figitumumab—Insulin-like growth factor I receptor antagonistAntagonist—
Ganitumab—Insulin-like growth factor I receptor antagonistAntagonist—
Istiratumab—Insulin-like growth factor I receptor inhibitorInhibitor—
KW-2450 free base—Insulin-like growth factor I receptor inhibitorInhibitor—
Linsitinib—Insulin-like growth factor I receptor inhibitorInhibitor—
Mecasermin—Insulin-like growth factor I receptor agonistAgonist—
Mecasermin rinfabate—Insulin-like growth factor I receptor agonistAgonist—
PL-225B—Insulin-like growth factor I receptor inhibitorInhibitor—
Robatumumab—Insulin-like growth factor I receptor antagonistAntagonist—
XL-228—Insulin-like growth factor I receptor inhibitorInhibitor—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Growth delay due to insulin-like growth factor I resistance
0.81
Abnormality of the skeletal system
0.61
Gout
0.54
Hereditary disease
0.52
Neurodegenerative disease
0.52
Type 2 diabetes mellitus
0.51
Growth delay
0.50
Smoking initiation
0.49
Prostate carcinoma
0.49
Neoplasm
0.44

Drugs and mechanisms are from ChEMBL CHEMBL1957 (CC BY-SA 3.0). Gene name, function (UniProt P08069, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.